\t\t\t<\/p>\n \t\t\t\t\t\t <\/p>\n \tRelated story \t\t\t\t\t<\/p>\n \t\t\t\t\tJohn Goodman Opens Up About Weighing Nearly 400 Pounds and the \u2018Vicious Cycle\u2019 of Drinking\t\t<\/p>\n <\/span><\/p><\/div>\n \t\t<\/a><\/p>\n<\/article>\n \t \n\tAmylin-based obesity drugs use an analogue of a hormone, amylin, released by the pancreas alongside insulin, per Yale Medicine. Amylin regulates your blood sugar and gives you a feeling of fullness by slowing down the rate at which food leaves your stomach, which helps to suppress your appetite. The effects are similar to a GLP-1 medication, but they work via different mechanisms: amylin-based drugs use an analogue of the pancreatic hormone amylin, while GLP-1s mimic or amplify the effect of glucagon-like peptide-1, which is released by your liver.<\/p>\n \n\tPetrelintide is a once-weekly injectable amylin analogue drug highlighted in the new study, a medication developed by Zealand Pharma in partnership with Roche. While reporting around the study highlighted how its side effects and weight loss<\/a> matched up against GLP-1 drugs, the drugs haven\u2019t been compared in a head-to-head trial. Still, we\u2019re able to draw a few tentative conclusions from the research.<\/p>\n \n\tThe recent study<\/a> on petrelintide, ZUPREME-1, was released in September as a randomized, double-blind, placebo-controlled Phase 2 dose-finding trial (funded by Zealand Pharma, the makers of petrelintide). It was conducted at 32 sites internationally, including public hospitals and private clinics in countries like the US, Poland, and Romania, and included 485 participants with obesity, with a mean BMI of 36.7 to 37 kg\/m2, and a mean body weight of about 107 kg (235 pounds). The participants\u2019 mean age was 48.<\/p>\n \n\tThe study found that after 42 weeks on petrelintide, participants had lost about 10% of their starting weight, on average, compared to just 1.7% for those participants on the placebo. Specifically, participants on the smaller, one-milligram dose lost 8.7% of their bodyweight, versus 10.5-10.7% on the seven-milligram dose. All participants (including those on the placebo) also received counseling on weight loss through diet and at least 150 minutes of exercise per week.<\/p>\n \n\tThe weight loss is lower than what patients on GLP-1\u2019s typically lose. Per Drugs.com<\/a>, people on semaglutide (like Ozempic and Wegovy) often lose, on average, 15-19% of their bodyweight; for people on tirzepatide (like Zepbound), it\u2019s around 20-21%. But notably, the study participants on pertrelintide lost this weight without<\/em> experiencing some of the grueling side effects that often come with GLP-1s. The less significant weight loss might be the tradeoff for lighter side effects.<\/p>\n \n\tThe study found that petrelintide\u2019s most common side effect was nausea, which was experience by 20% of participants on the drug (versus 6% on the placebo). Other side effects included vomiting (3% of petrelintide users) and diarrhea (7% of petrilintide users). But the researchers also found that at the maximally effective dose of pertrelintide (that seven-milligram mark), there was no vomiting reported at all \u2014 and none of the participants had to discontinue treatment due to GI side effects.<\/p>\n \n\t\u201cRates of nausea with petrelintide are less than half of those observed with GLP-1 medications,\u201d noted lead researcher Timothy Garvey, MD, of the University of Alabama at Birmingham, in an interview with HCPLive<\/a>. \u201cRates of constipation, diarrhea, and vomiting roughly approximated those observed in placebo,\u201d he continued. \u201cThis is a well-tolerated medication.\u201d<\/p>\n \n\tThe side effect conversation is an important one. The gastrointestinal side effects caused by GLP-1\u2019s lead to 41% of users to suffer in silence, self-adjust the medications, or even stop taking them altogether, according to a national survey from Oshi Health<\/a>.<\/p>\n \n\tPetrelintide isn\u2019t yet approved by the FDA, so it\u2019s not available yet in the US, and these results still need to be reproduced in further trials. But the news is looking positive: in phase 2b trial<\/a> results released earlier this month, 220 people with overweight or obesity and type 2 diabetes reported losing up to 9.5% of their bodyweight over 28 weeks, compared to 2% with placebo. The next step is to test the drug again in a Phase 3 trial.<\/p>\n \n\tIt\u2019s also worth noting again that we don\u2019t know how petrelintide performs in a head-to-head trial versus a GLP-1 drug \u2014 we can only compare studies of both drugs done separately. Still, if a weight-loss drug with potentially less intense side effects than a GLP-1 is piquing your interest, it\u2019s worth keeping an eye on petrelintide and talking to your doctor if it does become available.<\/p>\n<\/p><\/div>\n![\"John](\"https:\/\/www.sheknows.com\/wp-content\/themes\/vip\/pmc-sheknows-2020\/assets\/public\/lazyload-fallback.gif\")
<\/p><\/div>\n<\/p><\/div>\n
\n<\/span><\/p>\n
\n<\/section>\n<\/p>\n\n\t\tWhat are amylin-based obesity drugs, and what is petrelintide?\t<\/h2>\n
\n\t\tWhat did the study find?\t<\/h2>\n
\n\t\tSo what were the side effects of petrelintide?\t<\/h2>\n
\n\t\tWhat happens next?\t<\/h2>\n